<div id="readability-page-1"><p>In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on PMV Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$6.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Jones covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Corbus Pharmaceuticals, and Pelthos Therapeutics. According to TipRanks, Jones has an average return of <span>3.4%</span> and a 42.19% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on PMV Pharmaceuticals is a Strong Buy with an average price target of $5.00.</p></div>

PMVP

<p>Oppenheimer's Jeff Jones maintains a Buy rating on PMV Pharmaceuticals with a $6.00 price target. The analyst consensus is a Strong Buy with an average target of $5.00. Jones, who covers the Healthcare sector, has a 3.4% average return and a 42.19% success rate on stock recommendations.</p>

PMV Pharmaceuticals (PMVP) Gets a Buy from Oppenheimer